|Year : 2016 | Volume
| Issue : 5 | Page : 576-581
Metabolism-mediated interaction potential of standardized extract of Tinospora cordifolia through rat and human liver microsomes
Shiv Bahadur, Pulok K Mukherjee, SK Milan Ahmmed, Amit Kar, Ranjit K Harwansh, Subrata Pandit
Department of Pharmaceutical Technology, School of Natural Product Studies, Jadavpur University, Kolkata, West Bengal, India
|Date of Submission||12-Mar-2016|
|Date of Acceptance||21-Aug-2016|
|Date of Web Publication||16-Sep-2016|
Dr. Pulok K Mukherjee
Department of Pharmaceutical Technology, School of Natural Product Studies, Jadavpur University, Kolkata, West Bengal
Source of Support: None, Conflict of Interest: None
Objective: Tinospora cordifolia is used for treatment of several diseases in Indian system of medicine. In the present study, the inhibition potential of T. cordifolia extracts and its constituent tinosporaside to cause herb-drug interactions through rat and human liver cytochrome enzymes was evaluated.
Materials and Methods: Bioactive compound was quantified through reverse phase high-performance liquid chromatography, to standardize the plant extracts and interaction potential of standardized extract. Interaction potential of the test sample was evaluated through cytochrome P450-carbon monoxide complex (CYP450-CO) assay with pooled rat liver microsome. Influence on individual recombinant human liver microsomes such as CYP3A4, CYP2D6, CYP2C9, and CYP1A2 isozymes was analyzed through fluorescence microplate assay, and respective IC 50 values were determined.
Results: The content of tinosporaside was found to be 1.64% (w/w) in T. cordifolia extract. Concentration-dependent inhibition was observed through T. cordifolia extract. Observed IC 50 (μg/ml) value was 136.45 (CYP3A4), 144.37 (CYP2D6), 127.55 (CYP2C9), and 141.82 (CYP1A2). Tinosporaside and extract showed higher IC 50 (μg/ml) value than the known inhibitors. T. cordifolia extract showed significantly less interaction potential and indicates that the selected plant has not significant herb-drug interactions relating to the inhibition of major CYP450 isozymes.
Conclusions: Plant extract showed significantly higher IC 50 value than respective positive inhibitors against CYP3A4, 2D6, 2C9, and 1A2 isozymes. Consumption of T. cordifolia may not cause any adverse effects when consumed along with other xenobiotics.
Keywords: Cytochrome P450, human liver microsome, reverse phase high-performance liquid chromatography, Tinospora cordifolia, tinosporaside
|How to cite this article:|
Bahadur S, Mukherjee PK, Milan Ahmmed S K, Kar A, Harwansh RK, Pandit S. Metabolism-mediated interaction potential of standardized extract of Tinospora cordifolia through rat and human liver microsomes. Indian J Pharmacol 2016;48:576-81
|How to cite this URL:|
Bahadur S, Mukherjee PK, Milan Ahmmed S K, Kar A, Harwansh RK, Pandit S. Metabolism-mediated interaction potential of standardized extract of Tinospora cordifolia through rat and human liver microsomes. Indian J Pharmacol [serial online] 2016 [cited 2021 Jun 24];48:576-81. Available from: https://www.ijp-online.com/text.asp?2016/48/5/576/190758
Tinospora cordifolia (Family: Menispermaceae), also known as guduchi, is found in the tropics of Asia, Africa, and Australia. It is distributed throughout the tropical Indian subcontinent and most commonly used in Indian ayurvedic medicine as a tonic, vitalizer, and remedy for metabolic disorders.  This plant has been traditionally used in Ayurveda for the treatment of several diseases such as antidiabetic, dyspepsia, bile secretion stimulation, burning sensation, vomiting, vaginal and urethral discharges, and urinary diseases.  The major phytoconstituents are tinosporone, tinosporaside, tinosporic acid, cordifolisides A to E, syringen, giloin, giloininand, picrotene, bergenin, and arabinogalactan. T. cordifolia has been reported to exhibit diverse pharmacological activities such as immunomodulatory, anticancer, antiulcer, memory enhancer, antidepressant, anti-ischemic, antifertility, chemopreventive, hypolipidemic, neuroprotective, blood purifier, antipyretic, antihepatitis, cardiotonic, antimicrobial, antileishmanial, antiinflammatory, antispasmodic, antiarthritic, analgesic, diuretic, etc. 
The rate of metabolic biotransformation is one of the most important pharmacokinetic parameters that control the pharmacological action of the drug. Concomitantly administered dietary supplements or food substances may either induce or inhibit drug metabolizing enzymes, resulting in changes in the rate of drug metabolism.  For instance, one drug can inhibit the metabolism of another target drug, resulting in increased blood concentration of the target drug, which may lead to excessive accumulation and toxicity. Conversely, one drug can stimulate the metabolism of another victim drug, resulting in subtherapeutic plasma levels of that drug.  Cytochrome P450 (CYP450) enzymes are superfamily of monooxygenases located primarily in hepatocytes are important drug metabolizing systems in mammals.  Due to the central role of CYP450 catalyzed metabolism in drug clearance, the identification of potential of drug candidates as CYP substrate modulator (e.g., inhibitor and inducer) has been integrated, and the results will be helpful into the process of drug discovery and development. Therefore, the CYP450 enzymes inhibition might result alteration in drug metabolism and leading to various adverse effects.  The present study was performed to investigate the inhibition potential of T. cordifolia and its active constituent tinosporaside on the activities of CYP3A4, CYP2D6, CYP2C9, and CYP1A2 and in human liver microsomes and the mechanisms in vitro, which could be used to predict the probability of herb-drug interaction.
| » Materials and Methods|| |
Chemicals and Reagents
High-performance liquid chromatography (HPLC) grade methanol, acetic acid, triethylamine, and other analytical grade solvents were procured from Merck (Mumbai, India). 0.45 μm syringe filter and membrane filter were obtained from Phenomenex (Torrance, CA) and Millipore (Billerica, MA), respectively. Tinosporaside was purchased from Sigma chemicals (Steinheim, Germany). Vivid ® CYP450 Screening kit and Vivid ® substrates were purchased from Invitrogen Drug Discovery Solutions, USA. 96-well black microplate was obtained from NUNC (Roskilde, Denmark). Quinidine and sulfaphenazole were procured from Sigma (Steinheim, Germany). Ketoconazole and α-naphthoflavone were obtained from Merck (Mumbai, India).
Collection, Identification, and Processing of Plant Material
The aerial part of T. cordifolia was collected from Kolkata, India, and identified and authenticated by Dr. S. Rajan, field botanist, Ooty, Tamilnadu, India. A voucher specimen (JU-SNPS-1047) was deposited at the School of Natural product studies, Jadavpur University, Kolkata. The collected plant material was washed with distilled water, dried in room temperature, and then milled to a fine powder for preparation of extract.
Extraction of Plant Material
Hydroalcoholic extract of T. cordifolia was prepared by immersing 200 g coarsely powdered plant material in conical flasks containing 500 mL 70% aqueous ethanol, with occasional shaking at room temperature. The mixture was kept for 72 h and filtered, and the process was repeated until remaining residues colorless. The filtrate was concentrated under reduced pressure using a rotary evaporator (Yiela, Tokyo, Japan). The obtained extract was lyophilized to get a dry powder, and the final yield was found to be 11.78% (w/w). The dried extract was stored at 4°C in air-tight container until further use.
| » Standardization of Tinospora cordifolia Extract|| |
T. cordifolia extract was standardized through reverse phase HPLC (RP-HPLC). Lyophilized hydroalcoholic extract of T. cordifolia was accurately weighted, and volume of the solution was adjusted in a volumetric flask to obtain a concentration of 10 mg/mL with methanol as a stock solution. Then, it was subsequently diluted to get 1 mg/mL concentration HPLC analysis. The optimized mobile phase was composed of acetonitrile, and Milli-Q water in the ratio of 25:75 (v/v) with flow rate of 1 ml/min.
The HPLC system was comprised rheodyne-7725 injection valve with a sample loop (20 mL), vacuum degasser, quaternary pump, and photodiode array detector was used, with data acquisition by Empower™ 2 software (Waters 600, Milford, MA, USA). Chromatography was performed on a Spherisorb C18 column (250 mm × 4.6 mm, 5 mm; Waters, Ireland) fitted with a C18 guard column (10 mm × 3.0 mm). The sample elution was performed at 25°C and detected at the ultraviolet wavelength of 254 nm. The sample was analyzed by HPLC using 20 μL injection volume of a syringe (Hamilton Microliters; Switzerland). The pH meter (Orion 3-Star, Thermo-Scientific) was used to adjust the pH of the mobile phase. The amount of the phytoconstituent present in the sample was determined through the calibration curve. Calibration curve constructed by corresponding peak area of the standard was plotted against the concentration of standards by means of linear regression. Stock solution of standard compound was prepared by dissolving the known amount of tinosporaside in methanol at a concentration of 1 mg/mL.
| » Cytochrome P450 Inhibition Assay|| |
Preparation of Sample Solutions
The lyophilized extract of T. cordifolia was solubilized in ethanol and dimethyl sulfoxide (DMSO), and volume was adjusted to make a concentration of 10 mg/mL. The samples were examined to establish their influence on rat liver CYP450 enzymes activity. Tinosporaside (1 mg/mL) was also solubilized in ethanol and DMSO and used for inhibition assay. 5 μL of ketoconazole (100 μM) was used as positive control to compare the inhibitory activity with standard and extract of T. cordifolia. The experiment was performed as approved by the Institutional Animal Ethical Committee with the ethical guidelines as provided by the Committee (approval number: AEC/PHARM/1501/05/2015) for the Purpose of Control and Supervision of Experiment on Animals, India. Rat liver microsome (RLM) was isolated by the method described by Ponnusankar et al. 
Cytochrome P450-Carbon Monoxide Complex Assay
CYP450-carbon monoxide complex (CYP450-CO) assay was performed with pooled RLM in 96-well microplate. , The RLM was diluted with a required phosphoglycerol buffer (10 mM potassium phosphate, pH 7.4, 20% glycerol) and incubated with prepared extract (dissolved in ethanol and DMSO). On addition of NADPH-generating system (4.20 mg/ml of NADP + in solution of 100 mM glucose-6-phosphate, 100 mM MgCl2, and 100 U/ml glucose-6 phosphate dehydrogenase) reaction between extract and CYP450 was initiated. Two aliquots were placed in microplate wells, and one plate was designed as reduced P450 (P), and other one was reduced P450-CO complex (PC). The P-well was sealed with tape and kept out side of the chamber, whereas PC well was kept in CO chamber and incubated for 15 min (because both well should be separate during incubation period). After that the samples were reduced by addition of 0.5 M sodium hydrosulfite fresh solution. The visible appearance of PC sample was yellow while P sample remained colorless. The difference in the absorbance of samples at 450 and 490 nm was monitored using BIORAD microplate reader (Model 680XR). Ketoconazole was used as positive control, and proper solvent controls were used for the study. ,
Cytochrome P450 Enzymes Inhibition Assay
This study was performed in black 96 microplates through fluorogenic assays. The assay method was based on the previous reports by Pandit et al.  Briefly, 145 μl NADPH-CO factor mixture (1.3 mM NADP + , 66 mM MgCl 2s , and 66 mM glucose 6-phosphate) was added to each well of the first row of black 96-microwell plates. 7-benzyloxymethyloxy-3-cyanocoumarin (BOMCC) was used as substrate for CYP3A4 and CYP2C9. In case of CYP2D6 and CYP1A2, 7-ethoxymethoxy-3-cyanocoumarin (EOMCC) was used as substrate. 7-hydroxycoumarin and 7-hydroxy-3-cyanocoumarin by product were formed against BOMCC and EOMCC after the enzymatic reaction. Test samples were prepared in 0.1% DMSO and ethanol for CYP34 and 1A2 inhibition study. In case of CYP2D6 and 2C9, 0.01% organic solvents were used for the preparation of test sample. The concentrations of organic solvents were selected based on the recommended protocol of Vivid CYP450 enzymes screening kits (Invitrogen Drug Discovery Solutions, USA). In the final reaction mixture, the concentration of both the solvents was <0.1%, which was safe to use. Then, 100 μl of cofactor mixtures were added to all other wells except the blank. 5 μl of hydroalcoholic T. cordifolia extract solution was added to the first row of each well. Two-fold serial dilution was made for the concentration range of the 12.5-400 μg/ml and plates were incubated for 10 min at 37°C. Quinidine (1 μM), ketoconazole (10 μM), sulfaphenazole (10 μM), and α-naphthoflavone (3 μM) were used as positive inhibitors for CYP2D6, CYP3A4, CYP2C9, and CYP1A2, respectively.
Reaction was started by addition of 100 μl enzyme-substrate solution, which was prepared in phosphate buffer. After 30 min of incubation time, 0.5 M tris base was added to stop the reaction. Fluorescence intensity of the substrate was measured using appropriate excitation/emission (λ) of 405/460 using Biotek FLx 800 fluorescence microplate reader (Bio-Tek, USA). Generation of the products was linear over the range used for these assays, and the data obtained were analyzed using an Excel spreadsheet. Calculation of IC 50 values was based on the curves of mean enzyme activity versus inhibitor concentration. The percentage of inhibition and IC 50 was calculated based on the following formula. 
Percentage of inhibition = 100 − ([Signal of well − Blank]/[Solvent control − Blank] ×100)
IC 50 = ([(50 − LP) × (HC − LC)] + LC/[HP − LP])
Where LP = Low percentage of inhibition; HP = High percentage of inhibition; LC = Low concentration; HC = High concentration.
Statistical analysis was performed using the statistical functions of the GraphPad Prism® 5.0 software (CA, USA). The results were expressed in terms of mean ± standard error of mean. One-way analysis of variance test followed by Dunnett multiple comparisons test was followed. The values (P < 0.05) were considered statistically significant.
| » Results|| |
Consumption of herbal products for therapeutic benefit has been regulated by several laws in different countries and mostly lack of proper documentation for their safety, efficacy or standards, and quality control. The objective of the present work was to establish a rational procedure to screen the standardized extracts of T. cordifolia and its bioactive compound for CYP450 inhibiting activity. In the present study, we assayed the quantity of major bioactive constituent tinosporaside of T. cordifolia extract and their inhibition potential against different CYP isozymes.
Standardization of Tinospora cordifolia Extract
T. cordifolia extract was standardized by RP-HPLC under the isocratic conditions using the external standard calibration technique. Bioactive compound was identified by comparing with the respective retention time (Rt) of the tinosporaside as standard. Calibration curve was plotted by plotting peak areas against concentrations, and five standard marker ranges from 100 to 500 μg/ml. Standard compound shows a good linearity between concentrations and the peak area, with the correlation coefficient (r2 ) of 0.998. Chromatograms from HPLC analyses of the extract and their respective markers are shown in [Figure 1]. The optimum separation was achieved using the mobile system at the volume ratio of acetonitrile and Milli-Q water in the ratio of 75:25 (v/v) with a flow rate of 1 mL/min. Rt of tinosporaside was found to be 9.13 min. The percentage amounts of standard constituent (tinosporaside) present in the crude extract were found to be 1.64% (w/w).
|Figure 1: Reverse phase high-performance liquid chromatography chromatograms of tinosporaside and Tinospora cordifolia extract|
Click here to view
Interaction Study through CYP Enzymes
Cytochrome P450-carbon monoxide complex assay
The protein concentration in isolated RLMs was found to be 5.47 mg/ml that was estimated by modified biuret method. The CYP450 concentration of RLM was found to be 0.428 nmol/mg. The results on cytochrome inhibition assay through CYP450-CO complex method showed a concentration-dependent inhibition of cytochrome enzymes. Ketoconazole was used as positive inhibitor showed much more inhibition potential than T. cordifolia extract and biomarker tinosporaside. Inhibition potential of T. cordifolia extract that was being dissolve in DMSO showed higher percentage of inhibition than in ethanol [Figure 2]. Tinosporaside showed lower inhibition potential as compared to T. cordifolia extract in both DMSO and ethanol solvent. The result revealed that the interaction potential of T. cordifolia extract was more rather than its individually bioactive molecule tinosporaside with CYP450 that may be due to the effects of some other bioactive molecules present in the hydroalcoholic extract of T. cordifolia.
|Figure 2: Percentage inhibitory effects of Tinospora cordifolia extract, tinosporaside, and positive inhibitor on pooled rat liver microsomes, (Values are expressed as mean ± standard error of mean (n = 3); **P < 0.01: ***P < 0.001)|
Click here to view
Cytochrome P450 enzymes inhibition assay
Interactions potential of CYP microsomes has been performed through specific high-throughput screening assays. Concentrations range of the test substance and tinosporaside for the assay was from 12.5 to 400 μg/ml. T. cordifolia extract and its bioactive compound tinosporaside were evaluated for their capability to affect the pharmacokinetics properties of other conventional drugs when administered concomitantly. The interaction potential of the T. cordifolia extract has been deliberated through different CYP isozymes such as CYP3A4, CYP2D6, CYP2C9, and CYP1A2 to assay their inhibition potential. The principle of the assay was the ability of substrates to compete with different fluorogenic substrate for different CYP450 isoforms. Coumarin derivative generates fluorescent products after dealkylation by CYP isozymes, therefore, used as probe substrates.  Positive controls for individual mircosomes were used to confirm the precision of the assay. Testing the pure compounds indicated the overall activity explainable by compounds or caused by other constituents in the extract.  Samples were assayed in triplicate, and IC 50 (μg/ml) values were calculated [Table 1]. The results of the present study revealed that the T. cordifolia extract and its bioactive compound have less inhibition potential on these isozymes compared to their respective positive inhibitors. Enzyme inhibition studies showed that inhibition of CYP3A4, CYP2D9, CYP29, and CYP1A2 by T. cordifolia was concentration dependent [Figure 3] with IC 50 136.45, 144.37, 127.55, and 141.82 μg/ml, respectively.
|Figure 3: Concentration-dependent percentage inhibition of Tinospora cordifolia extract, tinosporaside, and positive inhibitors on drug metabolizing isozymes CYP3A4 (a), CYP2D6 (b), CYP2C9, (c) and CYP1A2 (d): (Values are in mean ± standard error of mean)|
Click here to view
|Table 1: IC50 (μg/ml) value of Tinospora cordifolia extract, tinosporaside, and positive inhibitors on the major drug metabolizing enzymes such as CYP3A4, CYP2D6, CYP2C9, and CYP1A2 |
Click here to view
| » Discussion|| |
Herbal medicines have been exploited as an important source of clinically relevant drugs for the treatment of several diseases. T. cordifolia is a popular medicinal plant and is frequently used as folk medicine in Indian System of Medicine.  However, its safety profile on herb-drug interaction aspects remained poorly understood. Till date, there is no safety evaluation or studies carried out to assess the effects of T. cordifolia on human drug metabolizing enzymes.
Considering the worldwide popularity of herbal medicines with the development of several herbal formulations with improved bioavailability, incidence of herb-drug interactions is predicted to be increased. Numerous case studies have been described detrimental herb-drug interactions which can lead to morbidity or even mortality. , Various herbs such as Ginkgo biloba, garlic, milk thistle, and St. John's wort have the potential to inhibit or induce human drug metabolizing enzymes through CYP450.  In the previous research reports from our laboratory, several medicinal plants have been studied for the CYP450 interaction potential. Ahmmed et al. (2016) has reported the CYP450 mediated inhibition potential of Swertia chirata (SC) and its active principle (ursolic acid). This study revealed that SC has less inhibition potential with two major drug metabolizing isozymes (CYP3A4 and CYP2D6). SC and ursolic acid showed significantly less inhibitory potential on RLM in a concentration-dependent manner.  In another study, Harwansh et al. (2014) reported the CYP450 interaction potential of trikatu, which is a very well-known polyherbal formulation in Ayurveda. Several concentrations of the trikatu formulation and its phytoconstituents showed less inhibitory activity on CYP3A4 and CYP2D6 isoenzymes as compared to the positive inhibitors. 
CYP450 isozymes (CYP3A4, CYP2C9, CYP2D6, and CYP1A2) are clinically most important metabolizing enzymes.  In the present study, an approach was made to evaluate the interaction potential of T. cordifolia through rat and human liver microsomes.  Standardization and chemoprofile of medicinal plants have more significance for validating its quality, safety, and to understand about the optimal concentrations of bioactive constituents present therein. The safety profile of T. cordifolia can be useful for both health-care professionals and consumers. The present study revealed that the concentration-dependent inhibition of the enzymes was observed with the both T. cordifolia extract and its bioactive compound tinosporaside. In fluorescence screening assay good linearity of concentration-dependent inhibition was found for T. cordifolia extract. Organic solvent (DMSO and ethanol) strongly interferes at higher concentration (5%) with isozymes (CYP3A4, CYP2D6, CYP2C9, and CYP1A2) therefore, a low concentration (0.01%) was used in this assay. , Ethanol and DMSO have been used as solvent, and no significant interaction was observed with spectral absorption, proper solvent control was used, and further solvent effect was neutralized by deionized water. , DMSO was used at lowest level to make sure the maximum solubility of the phytoconstituents. CYP450 interaction potential was slightly higher for the extract dissolved in DMSO compared to ethanol. T. cordifolia and its individual component showed less inhibitory activity in a concentration-dependent manner. The sites of interaction of active constituents from T. cordifolia extract with these isozymes are not known.
The present study demonstrated that T. cordifolia has less inhibition potential on the CYP3A4, CYP2C9, CYP2D6, and CYP1A2 isozymes in comparison with their respective inhibitors. Among all the test substances, T. cordifolia extract showed highest (IC 50 <0.01 mg/ml) interaction potential for all the isozymes; whereas tinosporaside (IC 50 >0.1 mg/ml) showed least interaction potential. IC 50 value indicated that there was no significant herb-drug interaction of T. cordifolia and tinosporaside. It can be concluded that T. cordifolia may have no significant interaction potential with the coadministered drugs. Thus, T. cordifolia can be used with the other medicines which are metabolized by these cytochrome enzymes. Therefore, the drugs clearance by these enzymes may not be influenced by the T. cordifolia extract. Further in vivo studies are necessary to evaluate the clinical significance of the interactions.
Financial Support and Sponsorship
Authors would like to express their gratitude to the Department of Biotechnology (DBT), Government of India, New Delhi, for providing TATA Innovation Fellowship (D.O.No. BT/HRD/35/01/04/2014) to PKM.
Conflicts of Interest
There are no conflicts of interest.
| » References|| |
Sharma P, Velu V, Indrani D, Singh RP. Effect of dried guduchi (Tinospora cordifolia
) leaf powder on rheological, organoleptic and nutritional characteristics of cookies. Food Res Int 2013;50:704-9.
Sangeetha MK, Priya CD, Vasanthi HR. Anti-diabetic property of Tinospora cordifolia
and its active compound is mediated through the expression of Glut-4 in L6 myotubes. Phytomedicine 2013;20:246-8.
Kumar V, Nagar S. Studies on Tinospora cordifolia
monosugars and correlation analysis of uronic acids by spectrophotometric methods and GLC. Carbohydr Polym 2014;99:291-6.
Lee SY, Lee JY, Kang W, Kwon KI, Park SK, Oh SJ, et al.
Cytochrome P450-mediated herb-drug interaction potential of Galgeun-tang. Food Chem Toxicol 2013;51:343-9.
Ponnusankar S, Pandit S, Babu R, Bandyopadhyay A, Mukherjee PK. Cytochrome P450 inhibitory potential of Triphala - A Rasayana from Ayurveda. J Ethnopharmacol 2011;133:120-5.
Mukherjee PK, Ponnusankar S, Pandit S, Hazam PK, Ahmmed M, Mukherjee K. Botanicals as medicinal food and their effects on drug metabolizing enzymes. Food Chem Toxicol 2011;49:3142-53.
Qi XY, Liang SC, Ge GB, Liu Y, Dong PP, Zhang JW, et al.
Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol 2013;56:392-7.
Choi SJ, Kim M, Kim SI, Jeon JK. Microplate assay measurement of cytochrome p450-carbon monoxide complexes. J Biochem Mol Biol 2003;36:332-5.
Ponnusankar S, Pandit S, Venkatesh M, Bandyopadhyay A, Mukherjee PK. Cytochrome P450 inhibition assay for standardized extract of Terminalia chebula
Retz. Phytother Res 2011;25:151-4.
Ahmmed SM, Mukherjee PK, Bahadur S, Kar A, Mukherjee K, Karmakar S, et al.
Interaction potential of Trigonella foenum graceum
through cytochrome P450 mediated inhibition. Indian J Pharmacol 2015;47:530-4.
Pandit S, Mukharjee PK, Mukharjee K, Gajbhiye R, Venkatesh M, Ponnusankar S, et al
. Cytochrome P450 inhibitory potential of selected Indian spices - Possible food drug interaction. Food Res Int 2012;45:69-74.
Pandit S, Mukherjee PK, Ponnusankar S, Venkatesh M, Srikanth N. Metabolism mediated interaction of a-asarone and Acorus calamus
with CYP3A4 and CYP2D6. Fitoterapia 2011;82:369-74.
Ahmmed SM, Mukherjee PK, Bahadur S, Harwansh RK, Kar A, Bandyopadhyay A, et al.
CYP450 mediated inhibition potential of Swertia chirata
: An herb from Indian traditional medicine. J Ethnopharmacol 2016;178:34-9.
Harwansh RK, Mukherjee K, Bhadra S, Kar A, Bahadur S, Mitra A, et al.
Cytochrome P450 inhibitory potential and RP-HPLC standardization of trikatu - A Rasayana from Indian Ayurveda. J Ethnopharmacol 2014;153:674-81.
Subash S, Seervi M, Lyer K, Anagha D. Assessment of rat hepatic cytochrome P450 induction and inhibition potential of chlorogenic acid. Indian J Pharm Educ Res 2011;45:32-40.
Choi EJ, Park JB, Yoon KD, Bae SK. Evaluation of the in vitro
potential of five berries (Bilberry, blueberry, cranberry, elderberry, and raspberry ketones) commonly used as herbal supplements to inhibit uridine diphospho-glucuronosyltransferase. Food Chem Toxicol 2014;72:13-9.
Iwata H, Tezuka Y, Kadota S, Hiratsuka A, Watabe T. Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit extract. Drug Metab Pharmacokinet 2005;20:34-45.
Sieniawska E, Baj T, Dudka J, Gieroba R, Swiatek L, Rajtar B, et al.
Cytotoxicity, antioxidant activity and an effect on CYP3A4 and CYP2D6 of Mutellina purpurea
L. extracts. Food Chem Toxicol 2013;52:188-92.
Kim H, Choi HK, Jeong TC, Jahng Y, Kim DH, Lee SH, et al.
Selective inhibitory effects of mollugin on CYP1A2 in human liver microsomes. Food Chem Toxicol 2013;51:33-7.
[Figure 1], [Figure 2], [Figure 3]